Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AssigneeThe Regents of the University of California
InventorsJames D. Marks, Isin N. Geren, Maria Consuelo Garcia, Jianlong Lou, Ali Razai
Life of this patent
Estimating the term…
Abstract
This invention provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
Claims28
1-31. (canceled)
An isolated antibody that specifically binds an epitope of a Botulinum neurotoxin (BoNT) that is specifically bound by an antibody expressed by clone 2B18.1, 1B18, B6, B6.1, 3E2, 3E6, 3E6.1, 4E16.1, 4E16, 4E17, 4E17.1, B12, B12.1, B12.2, 6A12, B1.1, B8, B8.1, 4B17, 1B22, 2A10, 3E1, 3E3, 3E4, 3E4.1, 3E5, 3E6, 3E6.1, 4E11, or 4E12.
Dependencies are inferred from the claim text.